IRIS

Aldicarb

CASRN 116-06-3 | DTXSID0039223

  • IRIS Summary (PDF) (24 pp, 161 K)
  • Status: EPA announced in a 2004 Federal Register Notice that chemicals used as pesticides would not be re-assessed by the IRIS Program. This entry in the IRIS database is preserved at the request of EPA program and regional offices. Additional toxicological information may be found under "Other EPA Information."

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (24 pp, 161 K) Last Updated: 11/01/1993

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Nervous 1 x 10 -3 Sweating as clinical sign of AChe inhibition NOAEL : 1 x 10-2
mg/kg-day
10 Medium

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (24 pp, 161 K)
Not assessed under the IRIS Program.

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (24 pp, 161 K) Last Updated: 08/22/1988

WOE Characterization Framework for WOE Characterization
D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986)
Basis:
  • Aldicarb was not found to induce statistically significant increases in tumor incidence in mice or rats in feeding studies or mice in a skin painting study. In the feeding studies there were, however, significant trends in pituitary tumors in female rats and fibrosarcomas in the male mouse. This evidence, together with the fact that less than maximum tolerated doses were used, indicates that the available assays are inadequate to assess the carcinogenic potential of aldicarb.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (24 pp, 161 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (24 pp, 161 K)

Not assessed under the IRIS Program.


Additional EPA toxicity information may be available by visiting the following sites:

You will need Adobe Reader to view some of the files on this page. See EPA's PDF page to learn more.

Contact Us to ask a question, provide feedback or report a problem.